Citi analyst Yigal Nochomovitz downgraded Atara Biotherapeutics (NASDAQ: ATRA) from Neutral to Sell with a price target of $3.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE